ACO Public Reporting

Transcription

1 ACO Public Reporting ACO Name and Location AHS ACO LLC (Atlantic Accountable Care Organization) 465 South Street, Suite 205 Morristown, NJ (973) Primary Contact Mr. David Gross Executive Director Composition of AHS ACO AHS ACO, LLC is a NJ limited liability company governed by its operating agreement and by the NJ Limited Liability Company Act. AHS ACO, LLC s members consist of AHS Hospital Corp., The Valley Hospital and certain physician/clinician members. AHS ACO Participants The following providers are participating in the AHS ACO (see attached.pdf).

2 AHS ACO Governing Body Governing Board Ira Monka, DO, ACO Participant, Practice Associates Medical Group** David Shulkin, MD ACO Participant, Practice Associates Medical Group ** (President - Morristown Medical Center*) Alan Lieber ACO Participant, Practice Associates Medical Group** (President - Overlook Medical Center*) Joseph DiPaolo ACO Provider/Supplier - Hospital Representative** (President - Newton Medical Center*) Deborah Zastocki ACO Provider/ Supplier Hospital Representative** (President - Chilton Medical Center*) Marc Goldberg ACO Participant, Valley Physician Services, Inc.** (The Valley Hospital/ The Valley Health System) Kathleen Rosen-Kerr, MD ACO Participant, Internal Medicine Pediatrics ** Susan Kaye, MD ACO Participant, Practice Associates Medical Group** Samir Shah, MD ACO Participant, Specialist- Premier Health Associates LLC** Timothy Brabston, MD ACO Participant, Medical Associates of North Jersey ** Richard Lucanie, MD ACO Participant, Valley Diagnostic Medical Center** Mary Herald Medicare Beneficiary Representative** John Feltz, MD Physician Member, Specialist, Lifeline Medical Associates, PA David Gross ACO Executive Director *Vice President -Atlantic Health System ** Voting Members AHS ACO Committees and Key Leadership Personnel Finance Committee Kevin Lenahan Health Information Technology (HIT) Mark Lederman Performance Improvement Committee John Feltz, MD Provider Integration & Beneficiary Engagement Arnold Pally, MD Nominating and Credentialing Committee Thomas Kloos, MD

3 Regional Advisory Boards Bergen Region: Richard Lucanie, MD Passaic Region: Timothy Brabston, MD Morris Region: Ira Monka, DO Sussex Region: Kenneth Roffe, DO Union Region: Samantha Pozner, MD Amount of Shared Savings/Losses Performance Year 1: $0 Performance Year 2: TBD Performance Year 3: TBD How Shared Savings Are Distributed The percentage set forth below represents an approximate value. The final decision regarding any Shared Savings distribution would be determined by the Governing Board. Note that in Performance Year 1, there will be no shared savings distribution. Operational expenses and reinvestment in infrastructure, care processes, and clinical integration: Variable % TBD Distribution to ACO participants o Hospitals 10% of residual after Operational Expenses/Reinvestment o Physicians 90% of residual after Operational Expenses/reinvestment Primary Care Physicians 80% of this pool Specialty Physicians 20% of this pool

4 Quality Performance Results 2013 Performance Summary Statistics Performance Measure ACO Performance Mean Performance Rate for All ACOs Rate Getting Timely Care, Appointments, and Information (ACO-1) How Well Your Doctors Communicate (ACO-2) Patients Rating of Doctor (ACO-3) Access to Specialists (ACO-4) Health Promotion and Education (ACO ) Shared Decision Making (ACO-6) Health Status/Functional Status (ACO-7) Risk Standardized, All Condition Readmissions (ACO-8) ASC Admissions: COPD or Asthma in Older Adults (ACO-9) ASC Admission: Heart Failure (ACO-10) Percent of Primary Care Providers who Qualified for EHR Incentive Payment (ACO-11) Medication Reconciliation (ACO-12) Falls: Screening for Fall Risk (ACO-13) Influenza Immunization (ACO-14) Pneumococcal Vaccination (ACO-15) Adult Weight Screening and Follow-up (ACO-16) Tobacco Use Assessment and Cessation Intervention (ACO-17) Depression Screening (ACO-18) Colorectal Cancer Screening (ACO-19) Mammography Screening (ACO-20) Proportion of Adults who had blood pressure screened in past 2 years (ACO-21) all the following criteria: Hemoglobin

5 A1c Control (HbA1c) (<8 percent) (ACO-22) Performance Measure all the following criteria: Low Density Lipoprotein (LDL) (< 100 mg/dl) (ACO-23) all the following criteria: Blood Pressure (BP) < 140/90 (ACO-24) all the following criteria: Tobacco Non- Use (ACO-25) all the following criteria: Aspirin Use (ACO-26) Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent) (ACO-27) Percent of beneficiaries with hypertension whose BP < 140/90 (ACO-28) Percent of beneficiaries with IVD with complete lipid profile and LDL control <100mg/dl (ACO-29) Percent of beneficiaries who use Aspirin or other antithrombotic (ACO-30) Beta-Blocker Therapy for LVSD (ACO-31) Percent of beneficiaries with CAD who met all of the following criteria: Drug Therapy for Lowering LDL- Cholesterol (ACO-32) Percent of beneficiaries with CAD who met all of the following criteria: (ACE) Inhibitor or (ARB) Therapy for Patients with CAD and Diabetes and/or (LVSD) (ACO-33) Mean Performance Rate for All ACOs Performance Summary Statistics: Pending 2015 Performance Summary Statistics: Pending